Nippon India Pharma Fund - IDCW - Direct Plan

Other Plans and Options
  • (-3.21%)Nav, as on 04-04-2025

  • Previous Nav

  • Net Change on 04-04-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview IDCW | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option 6.34 -7.93 13.23 19.59 28.16 18.00
BSE Health Care - TRI N/A N/A N/A N/A N/A N/A
BSE SENSEX - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option Jan 01, 2013 13.23 19.59 28.16 0.91 7,637.04
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Direct Plan - IDCW Option Jul 13, 2018 20.47 23.98 31.20 1.11 4,611.47
SBI Healthcare Opportunities Fund - Direct Plan - Income Distribution cum Capital Withdrawal Option (IDCW) Jan 01, 2013 20.46 24.33 30.35 0.97 3,312.89
DSP Healthcare Fund - Direct Plan - IDCW Nov 30, 2018 16.36 21.19 30.16 0.63 2,950.74
Mirae Asset Healthcare Fund Direct IDCW Jul 02, 2018 18.22 19.55 29.64 0.52 2,441.13
TATA India Pharma & Health Care Fund Direct Plan - Payout of Income Distribution cum capital withdrawal option Dec 28, 2015 15.99 20.80 27.75 0.74 1,103.99

Fund Holdings as on 28-February-2025

  • Sun Pharmaceutical Industries Limited

  • Divi's Laboratories Limited

  • Lupin Limited

  • Cipla Limited

  • Dr. Reddy's Laboratories Limited

  • Apollo Hospitals Enterprise Limited

  • Abbott India Limited

  • Vijaya Diagnostic Centre Limited

  • MedPlus Health Services Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Ajanta Pharma Limited

  • Gland Pharma Limited

  • Narayana Hrudayalaya Limited

  • Aurobindo Pharma Limited

  • Zydus Lifesciences Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Mankind Pharma Limited

  • Torrent Pharmaceuticals Limited

  • Pfizer Limited

  • Alkem Laboratories Limited

  • Thyrocare Technologies Limited

  • Sanofi India Limited

  • IPCA Laboratories Limited

  • Fortis Healthcare Limited

  • Triparty Repo

  • Sanofi Consumer Healthcare India Limited

  • Sai Life Sciences Limited

  • Suraksha Diagnostic Limited

  • Syngene International Limited

  • Biocon Limited

  • Dr. Lal Path Labs Limited

  • Orchid Pharma Limited

  • AstraZeneca Pharma India Limited

  • Indoco Remedies Limited

  • Emcure Pharmaceuticals Limited

  • Krishna Institute Of Medical Sciences Limited

  • Concord Biotech Limited

  • Cash Margin - CCIL

  • Net Current Assets

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Business Support

View More

Fund Manager

Most Recent Dividend

  • 21/02/2025

  • 26/02/2024

  • 28/02/2022

  • 01/03/2021

  • 02/03/2020

  • 05/03/2019

  • 05/03/2018

  • 06/03/2017

  • 08/03/2016

  • 02/02/2015

  • 17/02/2014

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 01-Jan-2013 and currently has an AUM of ₹7,637.04 crore. Nippon India Pharma Fund is benchmarked against BSE Health Care - TRI as primary index and BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended down ₹-5.1(-3.21%)yesterday to ₹153.7915.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan .

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097